^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Tarlox (tarloxotinib bromide) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tarloxotinib is a hypoxia-activated pan-HER kinase inhibitor active against a broad range of HER-family oncogenes
Published date:
12/22/2020
Excerpt:
Novel and existing patient-derived cell lines and xenografts harboring EGFR exon 20 insertion mutations, ERBB2 (HER2) mutations and amplification, and NRG1 fusions were tested in vitro and in vivo with tarloxotinib...Tarloxotinib-E inhibited cell signaling and proliferation in patient-derived cancer models in vitro...In vivo, tarloxotinib induced tumor regression or growth inhibition in multiple murine xenograft models.
DOI:
10.1158/1078-0432.CCR-20-3555
